SEK577.00
1.76% day before yesterday
Stockholm, Dec 27, 05:30 pm CET
ISIN
SE0007692850
Symbol
CAMX
Sector
Industry

Camurus Stock price

SEK577.00
+23.50 4.25% 1M
-16.50 2.78% 6M
+39.00 7.25% YTD
+51.50 9.80% 1Y
+430.60 294.13% 3Y
+492.90 586.09% 5Y
+511.00 774.24% 10Y
Stockholm, Closing price Fri, Dec 27 2024
+10.00 1.76%
ISIN
SE0007692850
Symbol
CAMX
Sector
Industry

Key metrics

Market capitalization SEK33.93b
Enterprise Value SEK31.20b
P/E (TTM) P/E ratio 126.09
EV/FCF (TTM) EV/FCF 102.69
EV/Sales (TTM) EV/Sales 18.47
P/S ratio (TTM) P/S ratio 20.09
P/B ratio (TTM) P/B ratio 10.90
Revenue growth (TTM) Revenue growth 4.89%
Revenue (TTM) Revenue SEK1.69b
EBIT (operating result TTM) EBIT SEK282.92m
Free Cash Flow (TTM) Free Cash Flow SEK303.81m
Cash position SEK2.75b
EPS (TTM) EPS SEK4.58
P/E forward 90.58
P/S forward 18.33
EV/Sales forward 16.86
Show more

Is Camurus a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Camurus Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Camurus forecast:

5x Buy
71%
2x Hold
29%

Analyst Opinions

7 Analysts have issued a Camurus forecast:

Buy
71%
Hold
29%

Financial data from Camurus

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
1,689 1,689
5% 5%
100%
- Direct Costs 144 144
9% 9%
9%
1,545 1,545
5% 5%
91%
- Selling and Administrative Expenses 516 516
40% 40%
31%
- Research and Development Expense 731 731
38% 38%
43%
298 298
49% 49%
18%
- Depreciation and Amortization 15 15
8% 8%
1%
EBIT (Operating Income) EBIT 283 283
50% 50%
17%
Net Profit 266 266
42% 42%
16%

In millions SEK.

Don't miss a Thing! We will send you all news about Camurus directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Camurus AB operates as a research based pharmaceutical company. The firm engages in the research, development and commercialization of specialty medicines. It provides its products for the treatment of severe and chronic conditions, which includes opioid dependence, pain, cancer and endocrine disorders. The company was founded by Kare Larsson in 1991 and is headquartered in Lund, Sweden.

Head office Sweden
CEO Sven Tiberg
Employees 213
Founded 2004
Website www.camurus.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today